Press releaseGlobe Newswire
Odyssey Therapeutics
ODTX · NASDAQ
$18.99+$0.89 (+4.92%)TodayMarket closed ·
Prev close $18.10
Latest news
- Press releaseGlobe Newswire
Odyssey Therapeutics to Present Design of Phase 2a Study Evaluating OD-001 in Combination with Vedolizumab at ACG 2026
- Press releaseGlobe Newswire
Odyssey Therapeutics Announces Oral Presentation of Additional Phase 2a Induction Data for OD-001 in Ulcerative Colitis at UEG Week 2026
- Press releaseGlobe Newswire
Odyssey Therapeutics to Participate in Stifel 2026 Virtual Immunology and Inflammation Forum
- Press releaseGlobe Newswire
Odyssey Therapeutics to Participate in Upcoming Investor Conferences
- Press releasePRNewswire
Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases
- Press releaseGlobe Newswire
Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- Press releaseGlobe Newswire
Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
- News
12 Health Care Stocks Moving In Friday's After-Market Session
- NewsAvi Kapoor
Doximity, Aeluma, PDF Solutions And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.